<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37936701</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Amplifying mRNA vaccines: potential versatile magicians for oncotherapy.</ArticleTitle><Pagination><StartPage>1261243</StartPage><MedlinePgn>1261243</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1261243</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1261243</ELocationID><Abstract><AbstractText>Cancer vaccines drive the activation and proliferation of tumor-reactive immune cells, thereby eliciting tumor-specific immunity that kills tumor cells. Accordingly, they possess immense potential in cancer treatment. However, such vaccines are also faced with challenges related to their design and considerable differences among individual tumors. The success of messenger RNA (mRNA) vaccines against coronavirus disease 2019 has prompted the application of mRNA vaccine technology platforms to the field of oncotherapy. These platforms include linear, circular, and amplifying mRNA vaccines. In particular, amplifying mRNA vaccines are characterized by high-level and prolonged antigen gene expression at low doses. They can also stimulate specific cellular immunity, making them highly promising in cancer vaccine research. In this review, we summarize the research progress in amplifying mRNA vaccines and provide an outlook of their prospects and future directions in oncotherapy.</AbstractText><CopyrightInformation>Copyright © 2023 Hu, Liu, Cheng, Bai, Mao, Xu and Liang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hu</LastName><ForeName>Chaoying</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Health Commission (NHC), Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Medical Products Administration (NMPA), Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Jianyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Health Commission (NHC), Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Medical Products Administration (NMPA), Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cheng</LastName><ForeName>Feiran</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Health Commission (NHC), Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Medical Products Administration (NMPA), Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Health Commission (NHC), Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Medical Products Administration (NMPA), Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Health Commission (NHC), Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Medical Products Administration (NMPA), Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Health Commission (NHC), Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Medical Products Administration (NMPA), Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Health Commission (NHC), Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Medical Products Administration (NMPA), Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000941">Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="Y">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000941" MajorTopicYN="N">Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019496" MajorTopicYN="Y">Cancer Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amplifying mRNA</Keyword><Keyword MajorTopicYN="N">cancer vaccine</Keyword><Keyword MajorTopicYN="N">in vitro transcription</Keyword><Keyword MajorTopicYN="N">tumor associated antigen</Keyword><Keyword MajorTopicYN="N">tumor-specific antigen</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>8</Day><Hour>3</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37936701</ArticleId><ArticleId IdType="pmc">PMC10626473</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1261243</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol (2020) 20(11):651–68. doi: 10.1038/s41577-020-0306-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0306-5</ArticleId><ArticleId IdType="pmc">PMC7238960</ArticleId><ArticleId IdType="pubmed">32433532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. . Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature (2023) 618(7963):144–50. doi: 10.1038/s41586-023-06063-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06063-y</ArticleId><ArticleId IdType="pmc">PMC10171177</ArticleId><ArticleId IdType="pubmed">37165196</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorentzen CL, Haanen JB, Met O, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol (2022) 23(10):e450–e8. doi: 10.1016/S1470-2045(22)00372-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(22)00372-2</ArticleId><ArticleId IdType="pmc">PMC9512276</ArticleId><ArticleId IdType="pubmed">36174631</ArticleId></ArticleIdList></Reference><Reference><Citation>Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, et al. . Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res (1995) 55(7):1397–400.</Citation><ArticleIdList><ArticleId IdType="pubmed">7882341</ArticleId></ArticleIdList></Reference><Reference><Citation>
Food and Drug Administration . (2023). Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine (Accessed July 13, 2023).</Citation></Reference><Reference><Citation>Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discovery (2018) 17(4):261–79. doi: 10.1038/nrd.2017.243</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>
Moderna . (2023). Available at: https://www.modernatx.com/media-center/all-media/blogs/fight-against-cancer (Accessed July 13, 2023).</Citation></Reference><Reference><Citation>Bai Y, Liu D, He Q, Liu J, Mao Q, Liang Z. Research progress on circular RNA vaccines. Front Immunol (2022) 13:1091797. doi: 10.3389/fimmu.2022.1091797</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1091797</ArticleId><ArticleId IdType="pmc">PMC9878156</ArticleId><ArticleId IdType="pubmed">36713460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballesteros-Briones MC, Silva-Pilipich N, Herrador-Canete G, Vanrell L, Smerdou C. A new generation of vaccines based on alphavirus self-amplifying RNA. Curr Opin Virol (2020) 44:145–53. doi: 10.1016/j.coviro.2020.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2020.08.003</ArticleId><ArticleId IdType="pmc">PMC7474593</ArticleId><ArticleId IdType="pubmed">32898764</ArticleId></ArticleIdList></Reference><Reference><Citation>Erasmus JH, Khandhar AP, O'Connor MA, Walls AC, Hemann EA, Murapa P, et al. . An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci Transl Med (2020) 12(555):eabc9396. doi: 10.1126/scitranslmed.abc9396</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abc9396</ArticleId><ArticleId IdType="pmc">PMC7402629</ArticleId><ArticleId IdType="pubmed">32690628</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization . (2023). Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (Accessed July 13, 2023).</Citation></Reference><Reference><Citation>Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines (Basel). (2021) 9(2):97. doi: 10.3390/vaccines9020097</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9020097</ArticleId><ArticleId IdType="pmc">PMC7911542</ArticleId><ArticleId IdType="pubmed">33525396</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, He Q, Yang J, Lu S, Mao Q, Gao F, et al. . B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates. Microbiol Spectr (2022) 10(5):e0226322. doi: 10.1128/spectrum.02263-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02263-22</ArticleId><ArticleId IdType="pmc">PMC9603226</ArticleId><ArticleId IdType="pubmed">36069561</ArticleId></ArticleIdList></Reference><Reference><Citation>Colter JS, Bird HH, Brown RA. Infectivity of ribonucleic acid from Ehrlich ascites tumour cells infected with Mengo encephalitis. Nature (1957) 179(4565):859–60. doi: 10.1038/179859a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/179859a0</ArticleId><ArticleId IdType="pubmed">13430718</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A. (1989) 86(16):6077–81. doi: 10.1073/pnas.86.16.6077</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.86.16.6077</ArticleId><ArticleId IdType="pmc">PMC297778</ArticleId><ArticleId IdType="pubmed">2762315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Berglund P, Rhodes G, Parker SE, Jondal M, Liljestrom P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine (1994) 12(16):1510–4. doi: 10.1016/0264-410X(94)90074-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(94)90074-4</ArticleId><ArticleId IdType="pubmed">7879415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, et al. . Cancer therapy using a self-replicating RNA vaccine. Nat Med (1999) 5(7):823–7. doi: 10.1038/10548</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/10548</ArticleId><ArticleId IdType="pmc">PMC1976249</ArticleId><ArticleId IdType="pubmed">10395329</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, et al. . Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest (2002) 109(3):409–17. doi: 10.1172/JCI0214364</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI0214364</ArticleId><ArticleId IdType="pmc">PMC150859</ArticleId><ArticleId IdType="pubmed">11828001</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby EJ, Hobeika AC, Niedzwiecki D, Rushing C, Hsu D, Berglund P, et al. . Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. J Immunother Cancer (2020) 8(2):e001662. doi: 10.1136/jitc-2020-001662</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001662</ArticleId><ArticleId IdType="pmc">PMC7661359</ArticleId><ArticleId IdType="pubmed">33177177</ArticleId></ArticleIdList></Reference><Reference><Citation>Beissert T, Perkovic M, Vogel A, Erbar S, Walzer KC, Hempel T, et al. . A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol Ther (2020) 28(1):119–28. doi: 10.1016/j.ymthe.2019.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2019.09.009</ArticleId><ArticleId IdType="pmc">PMC6953774</ArticleId><ArticleId IdType="pubmed">31624015</ArticleId></ArticleIdList></Reference><Reference><Citation>Samsa MM, Dupuy LC, Beard CW, Six CM, Schmaljohn CS, Mason PW, et al. . Self-amplifying RNA vaccines for Venezuelan equine encephalitis virus induce robust protective immunogenicity in mice. Mol Ther (2019) 27(4):850–65. doi: 10.1016/j.ymthe.2018.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2018.12.013</ArticleId><ArticleId IdType="pmc">PMC6453513</ArticleId><ArticleId IdType="pubmed">30770173</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock KM, Cheeseman HM, Szubert AJ, Libri V, Boffito M, Owen D, et al. . Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinicalMedicine (2022) 44:101262. doi: 10.1016/j.eclinm.2021.101262</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101262</ArticleId><ArticleId IdType="pmc">PMC8759012</ArticleId><ArticleId IdType="pubmed">35043093</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruggi G, Ulmer JB, Rappuoli R, Yu D. Self-amplifying mRNA-based vaccine technology and its mode of action. Curr Top Microbiol Immunol (2022) 440:31–70. doi: 10.1007/82_2021_233</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/82_2021_233</ArticleId><ArticleId IdType="pubmed">33861374</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Yang K, Li R, Zhang L. mRNA vaccine era-mechanisms, drug platform and clinical prospection. Int J Mol Sci (2020) 21(18):6582. doi: 10.3390/ijms21186582</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21186582</ArticleId><ArticleId IdType="pmc">PMC7554980</ArticleId><ArticleId IdType="pubmed">32916818</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Gascon A, del Pozo-Rodriguez A, Solinis MA. Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. Int J Nanomed (2014) 9:1833–43. doi: 10.2147/IJN.S39810</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S39810</ArticleId><ArticleId IdType="pmc">PMC3986288</ArticleId><ArticleId IdType="pubmed">24748793</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis NL, Willis LV, Smith JF, Johnston RE. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology (1989) 171(1):189–204. doi: 10.1016/0042-6822(89)90526-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(89)90526-6</ArticleId><ArticleId IdType="pubmed">2525837</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C, Levis R, Shen P, Schlesinger S, Rice CM, Huang HV. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science (1989) 243(4895):1188–91. doi: 10.1126/science.2922607</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2922607</ArticleId><ArticleId IdType="pubmed">2922607</ArticleId></ArticleIdList></Reference><Reference><Citation>Liljestrom P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnol (N Y). (1991) 9(12):1356–61. doi: 10.1038/nbt1291-1356</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1291-1356</ArticleId><ArticleId IdType="pubmed">1370252</ArticleId></ArticleIdList></Reference><Reference><Citation>Aberle JH, Aberle SW, Kofler RM, Mandl CW. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. J Virol (2005) 79(24):15107–13. doi: 10.1128/JVI.79.24.15107-15113.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.24.15107-15113.2005</ArticleId><ArticleId IdType="pmc">PMC1316042</ArticleId><ArticleId IdType="pubmed">16306582</ArticleId></ArticleIdList></Reference><Reference><Citation>Molenkamp R, Kooi EA, Lucassen MA, Greve S, Thijssen JC, Spaan WJ, et al. . Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins. J Virol (2003) 77(2):1644–8. doi: 10.1128/JVI.77.2.1644-1648.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.2.1644-1648.2003</ArticleId><ArticleId IdType="pmc">PMC140782</ArticleId><ArticleId IdType="pubmed">12502883</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijlman GP, Suhrbier A, Khromykh AA. Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin Biol Ther (2006) 6(2):135–45. doi: 10.1517/14712598.6.2.135</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.6.2.135</ArticleId><ArticleId IdType="pubmed">16436039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahola T, Kaariainen L. Reaction in alphavirus mRNA capping: formation of a covalent complex of nonstructural protein nsP1 with 7-methyl-GMP. Proc Natl Acad Sci U S A. (1995) 92(2):507–11. doi: 10.1073/pnas.92.2.507</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.2.507</ArticleId><ArticleId IdType="pmc">PMC42770</ArticleId><ArticleId IdType="pubmed">7831320</ArticleId></ArticleIdList></Reference><Reference><Citation>Das PK, Merits A, Lulla A. Functional cross-talk between distant domains of chikungunya virus non-structural protein 2 is decisive for its RNA-modulating activity. J Biol Chem (2014) 289(9):5635–53. doi: 10.1074/jbc.M113.503433</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.503433</ArticleId><ArticleId IdType="pmc">PMC3937639</ArticleId><ArticleId IdType="pubmed">24407286</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasiljeva L, Valmu L, Kaariainen L, Merits A. Site-specific protease activity of the carboxyl-terminal domain of Semliki Forest virus replicase protein nsP2. J Biol Chem (2001) 276(33):30786–93. doi: 10.1074/jbc.M104786200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M104786200</ArticleId><ArticleId IdType="pubmed">11410598</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotte B, Liu L, McInerney GM. The enigmatic alphavirus non-structural protein 3 (nsP3) revealing its secrets at last. Viruses (2018) 10(3):105. doi: 10.3390/v10030105</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10030105</ArticleId><ArticleId IdType="pmc">PMC5869498</ArticleId><ArticleId IdType="pubmed">29495654</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubach JK, Wasik BR, Rupp JC, Kuhn RJ, Hardy RW, Smith JL. Characterization of purified Sindbis virus nsP4 RNA-dependent RNA polymerase activity in vitro. Virology (2009) 384(1):201–8. doi: 10.1016/j.virol.2008.10.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.10.030</ArticleId><ArticleId IdType="pmc">PMC3107704</ArticleId><ArticleId IdType="pubmed">19036396</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietila MK, Hellstrom K, Ahola T. Alphavirus polymerase and RNA replication. Virus Res (2017) 234:44–57. doi: 10.1016/j.virusres.2017.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2017.01.007</ArticleId><ArticleId IdType="pubmed">28104453</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito LA, Kommareddy S, Maione D, Uematsu Y, Giovani C, Berlanda Scorza F, et al. . Self-amplifying mRNA vaccines. Adv Genet (2015) 89:179–233. doi: 10.1016/bs.adgen.2014.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.adgen.2014.10.005</ArticleId><ArticleId IdType="pubmed">25620012</ArticleId></ArticleIdList></Reference><Reference><Citation>Daemen T, Riezebos-Brilman A, Bungener L, Regts J, Dontje B, Wilschut J. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine (2003) 21(11-12):1082–8. doi: 10.1016/S0264-410X(02)00558-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(02)00558-3</ArticleId><ArticleId IdType="pubmed">12559783</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons JA, Sheahan BJ, Galbraith SE, Mehra R, Atkins GJ, Fleeton MN. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther (2007) 14(6):503–13. doi: 10.1038/sj.gt.3302889</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3302889</ArticleId><ArticleId IdType="pubmed">17167497</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka R, Tsuchiya N, Yajima N, Honma J, Hasegawa H, Tanaka R, et al. . Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg (2003) 99(4):746–53. doi: 10.3171/jns.2003.99.4.0746</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.2003.99.4.0746</ArticleId><ArticleId IdType="pubmed">14567611</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Madoz JR, Prieto J, Smerdou C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther (2005) 12(1):153–63. doi: 10.1016/j.ymthe.2005.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2005.02.011</ArticleId><ArticleId IdType="pubmed">15963931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer MG, Masner M, Casales E, Moreno M, Smerdou C, Chabalgoity JA. Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice. BMC Cancer. (2015) 15:620. doi: 10.1186/s12885-015-1618-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-015-1618-x</ArticleId><ArticleId IdType="pmc">PMC4562361</ArticleId><ArticleId IdType="pubmed">26347489</ArticleId></ArticleIdList></Reference><Reference><Citation>Velders MP, McElhiney S, Cassetti MC, Eiben GL, Higgins T, Kovacs GR, et al. . Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res (2001) 61(21):7861–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11691804</ArticleId></ArticleIdList></Reference><Reference><Citation>Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, et al. . Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PloS One (2010) 5(9):e12670. doi: 10.1371/journal.pone.0012670</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0012670</ArticleId><ArticleId IdType="pmc">PMC2937034</ArticleId><ArticleId IdType="pubmed">20844763</ArticleId></ArticleIdList></Reference><Reference><Citation>Avogadri F, Zappasodi R, Yang A, Budhu S, Malandro N, Hirschhorn-Cymerman D, et al. . Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer Immunol Res (2014) 2(5):448–58. doi: 10.1158/2326-6066.CIR-13-0220</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-13-0220</ArticleId><ArticleId IdType="pmc">PMC4406637</ArticleId><ArticleId IdType="pubmed">24795357</ArticleId></ArticleIdList></Reference><Reference><Citation>Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, Arrigale RR, et al. . A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res (2007) 13(13):3999–4008. doi: 10.1158/1078-0432.CCR-06-2202</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-06-2202</ArticleId><ArticleId IdType="pubmed">17606734</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res (2007) 67(3):1344–51. doi: 10.1158/0008-5472.CAN-06-2996</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-2996</ArticleId><ArticleId IdType="pubmed">17283172</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby EJ, Gwin W, Blackwell K, Marcom PK, Chang S, Maecker HT, et al. . Vaccine-induced memory CD8(+) T cells provide clinical benefit in HER2 expressing breast cancer: A mouse to human translational study. Clin Cancer Res (2019) 25(9):2725–36. doi: 10.1158/1078-0432.CCR-18-3102</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-18-3102</ArticleId><ArticleId IdType="pmc">PMC6497539</ArticleId><ArticleId IdType="pubmed">30635338</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby EJ, Acharya CR, Haddad AF, Rabiola CA, Lei G, Wei JP, et al. . Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and alphaPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Clin Cancer Res (2020) 26(17):4670–81. doi: 10.1158/1078-0432.CCR-20-0389</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-20-0389</ArticleId><ArticleId IdType="pmc">PMC7483405</ArticleId><ArticleId IdType="pubmed">32732224</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, et al. . An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest. (2010) 120(9):3234–41. doi: 10.1172/JCI42672</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI42672</ArticleId><ArticleId IdType="pmc">PMC2929723</ArticleId><ArticleId IdType="pubmed">20679728</ArticleId></ArticleIdList></Reference><Reference><Citation>Draghiciu O, Boerma A, Hoogeboom BN, Nijman HW, Daemen T. A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. Oncoimmunology (2015) 4(10):e1029699. doi: 10.1080/2162402X.2015.1029699</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2015.1029699</ArticleId><ArticleId IdType="pmc">PMC4589062</ArticleId><ArticleId IdType="pubmed">26451295</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, et al. . Phase II randomized study of CMB305 and atezolizumab compared with atezolizumab alone in soft-tissue sarcomas expressing NY-ESO-1. J Clin Oncol (2022) 40(12):1291–300. doi: 10.1200/JCO.20.03452</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.20.03452</ArticleId><ArticleId IdType="pubmed">34260265</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong SJ, et al. . Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med (2022) 28(8):1619–29. doi: 10.1038/s41591-022-01937-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01937-6</ArticleId><ArticleId IdType="pubmed">35970920</ArticleId></ArticleIdList></Reference><Reference><Citation>
ClinicalTrials.gov . (2023). Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05579275?term=JCXH-212&amp;draw=2&amp;rank=1 (Accessed July 03, 2023).</Citation></Reference><Reference><Citation>Beissert T, Koste L, Perkovic M, Walzer KC, Erbar S, Selmi A, et al. . Improvement of in vivo expression of genes delivered by self-amplifying RNA using vaccinia virus immune evasion proteins. Hum Gene Ther (2017) 28(12):1138–46. doi: 10.1089/hum.2017.121</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2017.121</ArticleId><ArticleId IdType="pmc">PMC5737720</ArticleId><ArticleId IdType="pubmed">28877647</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepini T, Pulichino AM, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K, et al. . Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J Immunol (2017) 198(10):4012–24. doi: 10.4049/jimmunol.1601877</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601877</ArticleId><ArticleId IdType="pmc">PMC5421303</ArticleId><ArticleId IdType="pubmed">28416600</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney AK, McKay PF, Shattock RJ. Structural components for amplification of positive and negative strand VEEV splitzicons. Front Mol Biosci (2018) 5:71. doi: 10.3389/fmolb.2018.00071</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2018.00071</ArticleId><ArticleId IdType="pmc">PMC6070733</ArticleId><ArticleId IdType="pubmed">30094239</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, et al. . Algorithm for optimized mRNA design improves stability and immunogenicity. Nature (2023) 621(7978):396–403. doi: 10.1038/s41586-023-06127-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06127-z</ArticleId><ArticleId IdType="pmc">PMC10499610</ArticleId><ArticleId IdType="pubmed">37130545</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Teague B, Zhang Y, Su Z, Porter E, Dobosh B, et al. . In vitro evolution of enhanced RNA replicons for immunotherapy. Sci Rep (2019) 9(1):6932. doi: 10.1038/s41598-019-43422-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-43422-0</ArticleId><ArticleId IdType="pmc">PMC6502795</ArticleId><ArticleId IdType="pubmed">31061426</ArticleId></ArticleIdList></Reference><Reference><Citation>Dariushnejad H, Ghorbanzadeh V, Akbari S, Hashemzadeh P. Design of a novel recombinant multi-epitope vaccine against triple-negative breast cancer. Iran BioMed J (2022) 26(2):160–74. doi: 10.52547/ibj.26.2.160</Citation><ArticleIdList><ArticleId IdType="doi">10.52547/ibj.26.2.160</ArticleId><ArticleId IdType="pmc">PMC8987416</ArticleId><ArticleId IdType="pubmed">35090304</ArticleId></ArticleIdList></Reference><Reference><Citation>Wach MM, Subjeck JR, Wang XY, Repasky E, Matsuzaki J, Yu H, et al. . Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients. Melanoma Res (2022) 32(2):88–97. doi: 10.1097/CMR.0000000000000796</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CMR.0000000000000796</ArticleId><ArticleId IdType="pmc">PMC8985419</ArticleId><ArticleId IdType="pubmed">35254331</ArticleId></ArticleIdList></Reference><Reference><Citation>Borobova EA, Antonets DV, Starostina EV, Karpenko LI, Ilyichev AA, Bazhan SI. Design of artificial immunogens containing melanoma-associated T-cell epitopes. Curr Gene Ther (2018) 18(6):375–85. doi: 10.2174/1566523218666181113112829</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1566523218666181113112829</ArticleId><ArticleId IdType="pubmed">30421674</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun QF, Zhao XN, Peng CL, Hao YT, Zhao YP, Jiang N, et al. . Immunotherapy for Lewis lung carcinoma utilizing dendritic cells infected with CK19 gene recombinant adenoviral vectors. Oncol Rep (2015) 34(5):2289–95. doi: 10.3892/or.2015.4231</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2015.4231</ArticleId><ArticleId IdType="pmc">PMC4583529</ArticleId><ArticleId IdType="pubmed">26323510</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, et al. . Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nat Biotechnol (2022) 40(11):1624–33. doi: 10.1038/s41587-022-01342-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-022-01342-x</ArticleId><ArticleId IdType="pmc">PMC9646498</ArticleId><ArticleId IdType="pubmed">35697807</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Li Z, Feng X, Yang D, Lin M. Advances in PSMA-targeted therapy for prostate cancer. Prostate Cancer Prostatic Dis (2022) 25(1):11–26. doi: 10.1038/s41391-021-00394-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41391-021-00394-5</ArticleId><ArticleId IdType="pubmed">34050265</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha SM, Barroca-Ferreira J, Passarinha LA, Socorro S, Maia CJ. The Usefulness of STEAP Proteins in Prostate Cancer Clinical Practice. In: Bott SRJ, Ng KL, editors. Prostate Cancer. Brisbane, Australia: Brisbane (AU) (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34181381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurupati RK, Zhou X, Xiang Z, Keller LH, Ertl HCJ. Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma. Cancer Immunol Immunother. (2018) 67(10):1533–44. doi: 10.1007/s00262-018-2201-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-018-2201-5</ArticleId><ArticleId IdType="pmc">PMC7080056</ArticleId><ArticleId IdType="pubmed">30051333</ArticleId></ArticleIdList></Reference><Reference><Citation>Salomon N, Vascotto F, Selmi A, Vormehr M, Quinkhardt J, Bukur T, et al. . A liposomal RNA vaccine inducing neoantigen-specific CD4(+) T cells augments the antitumor activity of local radiotherapy in mice. Oncoimmunology (2020) 9(1):1771925. doi: 10.1080/2162402X.2020.1771925</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2020.1771925</ArticleId><ArticleId IdType="pmc">PMC7458669</ArticleId><ArticleId IdType="pubmed">32923128</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao T, Cen Q, Lei H. A review on development of MUC1-based cancer vaccine. BioMed Pharmacother. (2020) 132:110888. doi: 10.1016/j.biopha.2020.110888</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110888</ArticleId><ArticleId IdType="pubmed">33113416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Z, Tan Z, Li M, Tao J, Guan E, Du J, et al. . Multi-functional nanocomplex codelivery of Trp2 and R837 to activate melanoma-specific immunity. Int J Pharm (2020) 582:119310. doi: 10.1016/j.ijpharm.2020.119310</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2020.119310</ArticleId><ArticleId IdType="pubmed">32276088</ArticleId></ArticleIdList></Reference><Reference><Citation>Berois N, Pittini A, Osinaga E. Targeting tumor glycans for cancer therapy: successes, limitations, and perspectives. Cancers (Basel). (2022) 14(3):645. doi: 10.3390/cancers14030645</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14030645</ArticleId><ArticleId IdType="pmc">PMC8833780</ArticleId><ArticleId IdType="pubmed">35158915</ArticleId></ArticleIdList></Reference><Reference><Citation>Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol (2012) 39(3):296–304. doi: 10.1053/j.seminoncol.2012.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminoncol.2012.02.010</ArticleId><ArticleId IdType="pmc">PMC3398615</ArticleId><ArticleId IdType="pubmed">22595052</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung DJ, Carvajal RD, Postow MA, Sharma S, Pronschinske KB, Shyer JA, et al. . Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial. Oncoimmunology (2017) 7(1):e1372081. doi: 10.1080/2162402X.2017.1372081</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2017.1372081</ArticleId><ArticleId IdType="pmc">PMC5739582</ArticleId><ArticleId IdType="pubmed">29296525</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, et al. . Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol (2019) 37(13):1051–61. doi: 10.1200/JCO.18.02031</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.18.02031</ArticleId><ArticleId IdType="pmc">PMC6494360</ArticleId><ArticleId IdType="pubmed">30817251</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkic-Zrna S, Probst J, et al. . Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. (2011) 34(1):1–15. doi: 10.1097/CJI.0b013e3181f7dbe8</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CJI.0b013e3181f7dbe8</ArticleId><ArticleId IdType="pubmed">21150709</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, et al. . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature (2020) 585(7823):107–12. doi: 10.1038/s41586-020-2537-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2537-9</ArticleId><ArticleId IdType="pubmed">32728218</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan TH, Sridhar S, Angell H, Jones E, Raymond A, Willis S, et al. . 269 Tumoral and peripheral landscape of Viral- versus Carcinogen-Driven Head and Neck Cancer. Regular young investigator award abstracts (2020) 8:A165–A6. doi: 10.1136/jitc-2020-SITC2020.0269</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-SITC2020.0269</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles D, Roche H, Martin M, Perren TJ, Cameron DA, Glaspy J, et al. . Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist (2011) 16(8):1092–100. doi: 10.1634/theoncologist.2010-0307</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2010-0307</ArticleId><ArticleId IdType="pmc">PMC3228158</ArticleId><ArticleId IdType="pubmed">21572124</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. . Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol (2005) 23(28):6854–64. doi: 10.1200/JCO.2005.17.186</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2005.17.186</ArticleId><ArticleId IdType="pubmed">16192577</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, et al. . Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO–the MIMOSA study. J Clin Oncol (2013) 31(12):1554–61. doi: 10.1200/JCO.2012.46.4057</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2012.46.4057</ArticleId><ArticleId IdType="pmc">PMC5795662</ArticleId><ArticleId IdType="pubmed">23478059</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, et al. . Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci (2015) 106(7):883–90. doi: 10.1111/cas.12674</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12674</ArticleId><ArticleId IdType="pmc">PMC4520640</ArticleId><ArticleId IdType="pubmed">25867139</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. . Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol (2017) 18(10):1373–85. doi: 10.1016/S1470-2045(17)30517-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(17)30517-X</ArticleId><ArticleId IdType="pubmed">28844499</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Moignic A, Malard V, Benvegnu T, Lemiegre L, Berchel M, Jaffres PA, et al. . Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells. J Control Release. (2018) 278:110–21. doi: 10.1016/j.jconrel.2018.03.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2018.03.035</ArticleId><ArticleId IdType="pubmed">29630987</ArticleId></ArticleIdList></Reference><Reference><Citation>Haabeth OAW, Blake TR, McKinlay CJ, Waymouth RM, Wender PA, Levy R. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc Natl Acad Sci U S A. (2018) 115(39):E9153–E61. doi: 10.1073/pnas.1810002115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1810002115</ArticleId><ArticleId IdType="pmc">PMC6166849</ArticleId><ArticleId IdType="pubmed">30201728</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol (2019) 10:3116. doi: 10.3389/fmicb.2019.03116</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.03116</ArticleId><ArticleId IdType="pmc">PMC6985034</ArticleId><ArticleId IdType="pubmed">32038557</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, et al. . Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature (2017) 547(7662):222–6. doi: 10.1038/nature23003</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23003</ArticleId><ArticleId IdType="pubmed">28678784</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang F, Schrors B, Lower M, Tureci O, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discovery (2022) 21(4):261–82. doi: 10.1038/s41573-021-00387-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00387-y</ArticleId><ArticleId IdType="pmc">PMC7612664</ArticleId><ArticleId IdType="pubmed">35105974</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng EM, Tsarovsky NW, Sondel PM, Rakhmilevich AL. Interleukin-12 as an in situ cancer vaccine component: a review. Cancer Immunol Immunother. (2022) 71(9):2057–65. doi: 10.1007/s00262-022-03144-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-022-03144-1</ArticleId><ArticleId IdType="pmc">PMC9276836</ArticleId><ArticleId IdType="pubmed">35024897</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Sun Q, Mei Y, Liu Y, Zhao L. Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy. Cancer Sci (2018) 109(2):279–88. doi: 10.1111/cas.13468</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13468</ArticleId><ArticleId IdType="pmc">PMC5797827</ArticleId><ArticleId IdType="pubmed">29224228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian T, Hao X, Li J, Wang H, Li C. B7-1 and GM-CSF enhance the anti-tumor immune effect of DC-tumor fusion vaccine in the treatment of prostate cancer. Med Oncol (2020) 37(11):107. doi: 10.1007/s12032-020-01433-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12032-020-01433-2</ArticleId><ArticleId IdType="pubmed">33136217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapenta C, Gabriele L, Santini SM. IFN-alpha-mediated differentiation of dendritic cells for cancer immunotherapy: advances and perspectives. Vaccines (Basel). (2020) 8(4):617. doi: 10.3390/vaccines8040617</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8040617</ArticleId><ArticleId IdType="pmc">PMC7711454</ArticleId><ArticleId IdType="pubmed">33086492</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z, Yang H, Tian Y, Liu Z, Sun F, Yang P. An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma. Front Oncol (2022) 12:975408. doi: 10.3389/fonc.2022.975408</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.975408</ArticleId><ArticleId IdType="pmc">PMC9606466</ArticleId><ArticleId IdType="pubmed">36313716</ArticleId></ArticleIdList></Reference><Reference><Citation>Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, et al. . Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res (2006) 66(12):6395–404. doi: 10.1158/0008-5472.CAN-05-4087</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-05-4087</ArticleId><ArticleId IdType="pubmed">16778218</ArticleId></ArticleIdList></Reference><Reference><Citation>Le N, Luk I, Chisanga D, Shi W, Pang L, Scholz G, et al. . IL-36G promotes cancer-cell intrinsic hallmarks in human gastric cancer cells. Cytokine (2022) 155:155887. doi: 10.1016/j.cyto.2022.155887</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2022.155887</ArticleId><ArticleId IdType="pubmed">35512531</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Shin AR, Sohn HJ, Cho HI, Kim TG. T cells modified with CD70 as an alternative cellular vaccine for antitumor immunity. Cancer Res Treat (2020) 52(3):747–63. doi: 10.4143/crt.2019.721</Citation><ArticleIdList><ArticleId IdType="doi">10.4143/crt.2019.721</ArticleId><ArticleId IdType="pmc">PMC7373873</ArticleId><ArticleId IdType="pubmed">32065848</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetab Boushehri MA, Lamprecht A. TLR4-based immunotherapeutics in cancer: A review of the achievements and shortcomings. Mol Pharm (2018) 15(11):4777–800. doi: 10.1021/acs.molpharmaceut.8b00691</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.8b00691</ArticleId><ArticleId IdType="pubmed">30226786</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer TM, Jimeno A, Wang D, LoRusso P, Tu Do K, Stemmer SM. Patel MReaApIsom-, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab. J Clin Oncol (2020) 38:3092–2. doi: 10.1200/JCO.2020.38.15_suppl.3092</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2020.38.15_suppl.3092</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnham DJ, Bullock N, Dass MS, Staffurth JN, Pearson HB. The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells (2020) 9(11):2342. doi: 10.3390/cells9112342</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9112342</ArticleId><ArticleId IdType="pmc">PMC7690430</ArticleId><ArticleId IdType="pubmed">33105713</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B, et al. . Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol (2021) 14(1):157. doi: 10.1186/s13045-021-01169-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-021-01169-0</ArticleId><ArticleId IdType="pmc">PMC8480024</ArticleId><ArticleId IdType="pubmed">34583722</ArticleId></ArticleIdList></Reference><Reference><Citation>Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res (1988) 48(6):1671–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">2830969</ArticleId></ArticleIdList></Reference><Reference><Citation>Piper M, Hoen M, Darragh LB, Knitz MW, Nguyen D, Gadwa J, et al. . Simultaneous targeting of PD-1 and IL-2Rbetagamma with radiation therapy inhibits pancreatic cancer growth and metastasis. Cancer Cell (2023) 41(5):950–69 e6. doi: 10.1016/j.ccell.2023.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2023.04.001</ArticleId><ArticleId IdType="pmc">PMC10246400</ArticleId><ArticleId IdType="pubmed">37116489</ArticleId></ArticleIdList></Reference><Reference><Citation>Samnuan K, Blakney AK, McKay PF, Shattock RJ. Design-of-experiments in vitro transcription yield optimization of selfAmplifying RNA. BioRxiv (2021). doi: 10.1101/2021.01.08.425833v1</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.08.425833v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Dousis A, Ravichandran K, Hobert EM, Moore MJ, Rabideau AE. An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts. Nat Biotechnol (2023) 41(4):560–8. doi: 10.1038/s41587-022-01525-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-022-01525-6</ArticleId><ArticleId IdType="pmc">PMC10110463</ArticleId><ArticleId IdType="pubmed">36357718</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H, Yu B, Jiang Y, Cheng R, Lu X, Wu H, et al. . Psychrophilic phage VSW-3 RNA polymerase reduces both terminal and full-length dsRNA byproducts in in vitro transcription. RNA Biol (2022) 19(1):1130–42. doi: 10.1080/15476286.2022.2139113</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476286.2022.2139113</ArticleId><ArticleId IdType="pmc">PMC9624206</ArticleId><ArticleId IdType="pubmed">36299232</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, et al. . mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther (2022) 7(1):166. doi: 10.1038/s41392-022-01007-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01007-w</ArticleId><ArticleId IdType="pmc">PMC9123296</ArticleId><ArticleId IdType="pubmed">35597779</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, An C, Bai Y, Li K, Liu J, Wang Q, et al. . A novel single-stranded RNA-based adjuvant improves the immunogenicity of the SARS-coV-2 recombinant protein vaccine. Viruses (2022) 14(9):1854. doi: 10.3390/v14091854</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14091854</ArticleId><ArticleId IdType="pmc">PMC9504790</ArticleId><ArticleId IdType="pubmed">36146661</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J, et al. . Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol (2019) 37(10):1174–85. doi: 10.1038/s41587-019-0247-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0247-3</ArticleId><ArticleId IdType="pubmed">31570898</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Medical Products Administration . (2023). Available at: https://www.nmpa.gov.cn/yaopin/ypggtg/20200814230916157.html (Accessed July 13, 2023).</Citation></Reference><Reference><Citation>
US Pharmacopeia . (2023). Available at: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/usp-nfnotices/gc-xxx-analytical-procedures-mRNA-vaccines.pdf (Accessed July 13, 2023).</Citation></Reference><Reference><Citation>
World Health Organization  . Available at: https://www.who.int/docs/default-source/biologicals/ecbs/reg-considerations-on-rna-vaccines_1st-draft_pc_tz_22122020.pdf?sfvrsn=c13e1e20_3 (Accessed July 13, 2023).</Citation></Reference><Reference><Citation>
COVID-19 Vaccine Tracker (2023). Available at: https://covid19.trackvaccines.org/ (Accessed July 13, 2023).</Citation></Reference><Reference><Citation>
World Health Organization . (2023). Available at: https://www.who.int/news/item/09-07-2021-gacvs-guidance-myocarditis-pericarditis-covid-19-mrna-vaccines (Accessed July 13, 2023).</Citation></Reference><Reference><Citation>
Science (2023). Available at: https://www.science.org/content/article/suspicions-grow-nanoparticles-pfizer-s-covid-19-vaccine-trigger-rare-allergic-reactions (Accessed July 13, 2023).</Citation></Reference><Reference><Citation>Santiago TC, Purvis IJ, Bettany AJ, Brown AJ. The relationship between mRNA stability and length in Saccharomyces cerevisiae. Nucleic Acids Res (1986) 14(21):8347–60. doi: 10.1093/nar/14.21.8347</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/14.21.8347</ArticleId><ArticleId IdType="pmc">PMC311863</ArticleId><ArticleId IdType="pubmed">3537957</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel S, Kis Z, Kontoravdi C, Shah N. Quality by Design for enabling RNA platform production processes. Trends Biotechnol (2022) 40(10):1213–28. doi: 10.1016/j.tibtech.2022.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2022.03.012</ArticleId><ArticleId IdType="pubmed">35491266</ArticleId></ArticleIdList></Reference><Reference><Citation>
U.S. Pharmacopeia / National Formulary (2023). Available at: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/usp-nf-notices/gc-1220-pre-post-20210924.pdf (Accessed July 13, 2023).</Citation></Reference><Reference><Citation>
International Conference on Harmonization (2023). Available at: https://database.ich.org/sites/default/files/ICH_Q14_Document_Step2_Guideline_2022_0324.pdf (Accessed July 13, 2023).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>